BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33645372)

  • 1. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
    Salim A; Tapia Rico G; Shaikh A; Brown MP
    Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
    Seki M; Kitano S; Suzuki S
    Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Distinctive Disease Entity of Neurological Adverse Events Associated with Immune Checkpoint Inhibitors].
    Seki M; Suzuki S
    Brain Nerve; 2021 Jan; 73(1):35-46. PubMed ID: 33361512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
    Suzuki S
    Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
    Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
    J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
    Xu M; Nie Y; Yang Y; Lu YT; Su Q
    Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases.
    Snavely A; Pérez-Torres EJ; Weber JS; Sandigursky S; Thawani SP
    J Neurol Sci; 2022 Jul; 438():120275. PubMed ID: 35597082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
    Aoun R; Gratch D; Kaminetzky D; Kister I
    Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
    Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
    J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review.
    Ghosh N; Chan KK; Jivanelli B; Bass AR
    J Clin Rheumatol; 2022 Mar; 28(2):e498-e505. PubMed ID: 34371516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologic complications of immune checkpoint inhibitors.
    Haugh AM; Probasco JC; Johnson DB
    Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
    Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.
    Anderson D; Beecher G; Nathoo N; Smylie M; McCombe JA; Walker J; Jassal R
    Neurooncol Pract; 2019 Sep; 6(5):340-345. PubMed ID: 31555448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.
    Li Y; Zhang X; Zhao C
    Biomed Res Int; 2021; 2021():9800488. PubMed ID: 34458371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.